Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy
Autore:
Johnson, LN; Guy, ME; Krohel, GB; Madsen, RW;
Indirizzi:
Univ Missouri, Neuroophthalmol Unit, Mason Eye Inst, Columbia, MO 65212 USA Univ Missouri Columbia MO USA 65212 ason Eye Inst, Columbia, MO 65212 USA Albany Med Ctr, Lions Eye Inst, Neuroophthalmol Unit, Albany, NY USA Albany Med Ctr Albany NY USA Inst, Neuroophthalmol Unit, Albany, NY USA Univ Missouri, Biostat Unit, Columbia, MO 65212 USA Univ Missouri Columbia MO USA 65212 Biostat Unit, Columbia, MO 65212 USA
Titolo Testata:
OPHTHALMOLOGY
fascicolo: 3, volume: 107, anno: 2000,
pagine: 521 - 526
SICI:
0161-6420(200003)107:3<521:LMIVLI>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHOROIDAL BLOOD-FLOW; EDINGER-WESTPHAL; DOPAMINE DEFICIENCY; CHILDHOOD AMBLYOPIA; PARKINSONS-DISEASE; GLUTAMATE; NUCLEUS; PLASTICITY; CARBIDOPA; SCOTOMAS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Johnson, LN Univ Missouri, Neuroophthalmol Unit, Mason Eye Inst, Columbia,MO 65212 USA Univ Missouri Columbia MO USA 65212 t, Columbia, MO 65212 USA
Citazione:
L.N. Johnson et al., "Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy", OPHTHALMOL, 107(3), 2000, pp. 521-526

Abstract

Objectives To study the effect of levodopa in improving visual function inpatients treated within 45 days of onset of nonarteritic anterior ischemicoptic neuropathy (NAION),Designs Nonrandomized, retrospective, comparative trial. Participants: The study involved 37 patients with NAION of less than 45 days duration. Methods: Eighteen patients who had been treated with levodopa were assigned to the case group, and 19 untreated patients were assigned to the controlgroup. Snellen visual acuity converted to logMAR and mean deviation on Humphrey automated perimetry (Program 24-2, Humphrey Instruments, San Leardro,CA) were evaluated at the initial and 6-month visits. Interventions The 18 patients in the case group were administered a capsule of 100 mg levodopa/25 mg carbidopa (Sinemet 25-100) three times daily for3 weeks. Main Outcome Measures: The primary outcome measures were changes in visualacuity and visual field at 6 months from baseline. Improvement in visual acuity was defined as a difference of -0.3 logMAR or less between the B-month and initial visual acuities, whereas worsened visual acuity was a difference of +0.3 logMAR or more. Each 0.3 LogMar represented a doubling of the visual angle, i.e., a change by three lines on the eye chart, Improvement invisual field was defined as a difference in mean deviation of +3.0 dB or more between the B-month and initial visual field tests, whereas worsened visual field was a difference in mean deviation of -3.0 dB or less. Results: The proportions of patients with worsened, unchanged, and improved visual acuity at 6 months were compared for the levodopa and control groups. There was a significant difference (P = 0.012) between the groups. Examination ofthe proportions showed that a higher proportion of patients who received levodopa had improved visual acuity with a corresponding lower proportion having worsened visual acuity as compared with the control patients. Ten of 13 patients (76.9%) in the levodopa group with 20/40 visual acuity or worse at baseline had improved visual acuity at 6 months, and none of the 18 patients had worsened visual acuity. In contrast, 3 of 10 control patients (30%) with 20/40 visual acuity or worse at baseline had improved visual acuity at 6 months, and 3 of 19 control patients (16.3%) had worsened visual acuity. The proportions of patients with worsened, unchanged, and improved visual fields at 6 months were compared for the levodopa and control groups. There was no significant difference between the groups (P = 0.25),Conclusions: Patients treated with levodopa within 45 days of onset of NAION were more likely to experience improvement and less likely to have worsened visual acuity than untreated patients. Levodopa appears to be beneficial in the treatment of recent-onset NAION. (C) 2000 by the American Academy of Ophthalmology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 13:00:54